Skip to content
  • Tuesday, 30 June 2026
  • 8:24 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Gilead Sciences Reports Robust Q1 2026 Performance Driven by Strong HIV Portfolio and Promising PrEP Launches
Pharmaceutical R&D

Gilead Sciences Reports Robust Q1 2026 Performance Driven by Strong HIV Portfolio and Promising PrEP Launches

Teuku Ryan May 9, 2026 0

Gilead Sciences has commenced 2026 with a demonstrably strong first quarter, reporting significant revenue growth primarily fueled by its leading…

Read More
SLAS 2026: Orchestration platforms, API-first instruments and the rise of semiautonomous labsEvidence for Endogenous Collagen in Edmontosaurus Fossil BoneHere’s Why WebMCP is ExcitingHKUMed Researchers Identify Piezo1 Protein as the Key Exercise Sensor in Bone Maintenance and Potential Target for Osteoporosis Treatment
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveHigh-Dimensional Topological Structures Discovered in Entangled Photons Offer New Framework for Quantum Information StabilityWater-in-Diesel Emulsion Technology Offers Significant Emissions Reduction Potential Without Engine Modification
Glioblastoma Research Reveals Skull Erosion and Immune System Reprogramming Reshaping Treatment StrategiesPioneering Sequencing by Synthesis: David Klenerman Reflects on a Decade of Innovation and the Future of BiotechDiabetes to MASH: the specimens behind GLP-1’s widening rosterSeven Pharma Companies Selected for FDA PreCheck Pilot Program to Bolster U.S. Drug Supply Chain
YOU MAY HAVE MISSED
Stem Cell & Regenerative Medicine
Glioblastoma Research Reveals Skull Erosion and Immune System Reprogramming Reshaping Treatment Strategies
Dwi Wanna Jun 30, 2026
Biotech & Genetic Research
Pioneering Sequencing by Synthesis: David Klenerman Reflects on a Decade of Innovation and the Future of Biotech
Jia Lissa Jun 30, 2026
Laboratory Automation & Robotics
Diabetes to MASH: the specimens behind GLP-1’s widening roster
Lana Keisha Jun 30, 2026
Pharmaceutical R&D
Seven Pharma Companies Selected for FDA PreCheck Pilot Program to Bolster U.S. Drug Supply Chain
Teuku Ryan Jun 30, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ